Roche’s $725M Seragon deal hasn’t gone as planned
Moving right along... Roche quietly disclosed in its Q1 financial report that it has scrapped a Phase 2 breast cancer asset, acquired in a $725 million buyout of Seragon Pharmaceuticals.
Moving right along... Roche quietly disclosed in its Q1 financial report that it has scrapped a Phase 2 breast cancer asset, acquired in a $725 million buyout of Seragon Pharmaceuticals.